Dupilumab Efficacy on Bronchial Inflammation, Small Airways Disfunction and Mucous Secretion

Sponsor
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Study ID
NCT05787678
Status
Unknown

Conditions

  • Asthma; Eosinophilic

Eligibility Criteria

Sex
ALL
Age
18 Years - 80 Years
Healthy Volunteers
Not accepted

Interventions

  • Dupilumab — BIOLOGICAL
    600 mg (two 300 mg injections), followed by 300 mg monthly

Study Details

Unicentric prospective real life study designed to analyse the efficacy of Dupilumab to reduce bronchial inflammation of asthma measured by inflammatory cell counts obtained in induced sputum and other related characteristics (small airway dysfunction and mucin production) in uncontrolled severe asthma patients in the real life setting without control group

Key Dates

Start date
Oct 1, 2023
Status verified
Jan 2024
Primary completion
Oct 31, 2024
Completion
Dec 31, 2024

Study Design

Enrollment
30 participants (estimated)

Primary Outcome Measure

Number of bronchial inflammatory cells [ Time Frame: 1 year ]

Related Studies